Holen Sie sich die Stockscreener-App
232.30
1.73%
3.94
Vorhandelsmarkt:
230.01
-2.29
-0.99%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$228.36
Offen:
$228.36
24-Stunden-Volumen:
105.66K
Relative Volume:
0.49
Marktkapitalisierung:
$4.65B
Einnahmen:
$268.09M
Nettoeinkommen (Verlust:
$124.45M
KGV:
39.81
EPS:
5.8347
Netto-Cashflow:
$38.05M
1W Leistung:
-0.01%
1M Leistung:
+16.39%
6M Leistung:
+22.02%
1J Leistung:
+118.43%
1-Tages-Spanne:
$228.36
$233.06
1-Wochen-Bereich:
$220.06
$236.22
52-Wochen-Spanne:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
232.30 | 4.65B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | BofA Securities | Buy |
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand CEO joins Palvella chief at May 6 investor fireside chat - Stock Titan
Ligand to Participate in May Investor Conferences - Yahoo Finance
Ligand to buy XOMA Royalty for $39/share - MSN
Ligand Pharmaceuticals CLO Andrew Reardon sells $1.16m in stock - Investing.com
CLO Andrew Reardon nets 5,000-share sale at Ligand (NASDAQ: LGND) - Stock Titan
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing - The Motley Fool
MSN Money - MSN
LGND PE Ratio & Valuation, Is LGND Overvalued - Intellectia AI
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
Ligand Pharma Ends TR‑Beta License With Viking Therapeutics - The Globe and Mail
LGND (NASDAQ) Rule 144 notice lists 467 common shares and dated sales - Stock Titan
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND) - Stock Titan
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ligand bets on royalty growth with XOMA buyout worth over $700 million - MSN
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event - Stock Titan
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $289 - GuruFocus
HC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals is buying Xoma for nearly $740 million - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownHere's Why - MarketBeat
LGND: XOMA Buy Adds 100+ Assets - Smartkarma
Moody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ - MSN
LGND Maintained by RBC Capital -- Price Target Raised to $252 - GuruFocus
Ligand to acquire XOMA Royalty - The Pharma Letter
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount - Yahoo Finance
RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating - Moomoo
RBC Capital raises Ligand Pharma stock price target on XOMA deal - Investing.com Canada
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - Yahoo Finance
Why Ligand's $739M Xoma buy matters for growth - Axios
BofA raises Ligand Pharma stock price target on XOMA acquisition - Investing.com
Stifel raises Ligand Pharma stock price target on XOMA acquisition - Investing.com UK
BofA raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com Canada
Stifel raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com India
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million - 104.1 WIKY
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
Ligand Pharmaceuticals Incorporated entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $470 million from BVF Partners L.P. and others. - marketscreener.com
Ligand Pharmaceuticals Acquires Zoma for $740 Million - GuruFocus
Ligand Pharmaceuticals (LGND) to Acquire Xoma Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals stock hits 52-week high at 240.25 USD By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs - TradingView
Ligand strikes $739M deal for Xoma Royalty - Axios
Ligand Pharmaceuticals to Acquire Xoma Royalty for 739 Million Dollars - HarianBasis.co
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal - Stock Titan
Ligand Pharmaceuticals (LGND) to Acquire XOMA Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals buying Xoma Royalty for $739 million - Yahoo Finance
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):